Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Sodium Channel>>Rimeporide hydrochloride (EMD-87580 hydrochloride)

Rimeporide hydrochloride (EMD-87580 hydrochloride) (Synonyms: EMD-87580 hydrochloride)

Catalog No.GC31449

Rimeporide hydrochloride (EMD-87580 hydrochloride) (EMD-87580 hydrochloride) is a potent and selective inhibitor of the Na+/H+ exchanger (NHE-1).

Products are for research use only. Not for human use. We do not sell to patients.

Rimeporide hydrochloride (EMD-87580 hydrochloride) Chemical Structure

Cas No.: 187870-95-7

Size Price Stock Qty
1mg
$175.00
In stock
5mg
$358.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Rimeporide hydrochloride (EMD-87580 hydrochloride) is a potent and selective inhibitor of the Na+/H+ exchanger (NHE-1).

Blocking NHE-1 activity has been shown to decrease intracellular Na+ and Ca2+ overload and pH and Rimeporide (EMD-87580) represents a new therapeutic option for duchenne muscular dystrophy (DMD). Rimeporide (EMD-87580) is expected to act as a muscle-sparing agent and its mode of action means that it is mutation independent[1].

[1]. F.Porte-Thomé, et al. Development of Rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy. Neuromuscular Disorders. October 2015 Oct 25:259-260.

Reviews

Review for Rimeporide hydrochloride (EMD-87580 hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rimeporide hydrochloride (EMD-87580 hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.